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We show the distribution of severe acute respiratory 
syndrome coronavirus-2 (SARS-CoV-2) genetic clades 
over time and between countries and outline poten-
tial genomic surveillance objectives. We applied three 
genomic nomenclature systems to all sequence data 
from the World Health Organization European Region 
available until 10 July 2020. We highlight the impor-
tance of real-time sequencing and data dissemination 
in a pandemic situation, compare the nomenclatures 
and lay a foundation for future European genomic sur-
veillance of SARS-CoV-2.
During the coronavirus disease (COVID-19) pandemic, 
whole genome sequencing (WGS) has been used 
extensively by laboratories all over the world to char-
acterise the virus. To be able to implement continuous 
monitoring of genetic changes through WGS as part of 
surveillance at the European level, surveillance objec-
tives and virus nomenclatures need to be defined. In 
this report, we applied the available nomenclatures to 
the European subset of the GISAID dataset to describe 
broad geographical and temporal trends in the distri-
bution of SARS-CoV-2 genetic clades during the first 
half of 2020 and we discuss potential genomic surveil-
lance objectives at the European level.
 
Genome data availability during the 
COVID-19 pandemic
The COVID-19 pandemic is the first pandemic where 
WGS capacity has been widely available to the pub-
lic health sector from the beginning. Since the first 
genomes were published in January 2020 [1-4], the 
number of available sequences has rapidly increased 
to more than 63,000 complete genome sequences 
available in GISAID as at 10 July [5]. The World Health 
Organization (WHO) European Region has been an 
active contributor, with around 39,000 complete 
genome sequences from 35 countries published in 
GISAID, with a median time of 40 days from sample 
collection to publication according to the GISAID col-
lection and submission dates. Of those sequences, 8% 
were published within 2 weeks of collection and 0.6% 
of sequences were published within 1 week of collec-
tion. Supplementary Figure S1 summarises the number 
of genomes sampled and submitted per month. A 
detailed account of the turnaround time for each 
country is shown in  Supplementary Figure S2. This 
demonstrates that with enough resources, it is pos-
sible to set up and perform real-time WGS and global 
analysis of a newly emerged virus.
 
2 www.eurosurveillance.org
Figure 1
Schematic comparison of the GISAID, Nextstrain and cov-lineages.org nomenclatures for SARS-CoV-2 sequences of world-
wide origin, February–July 2020
SNP: single nucleotide polymorphism.
A schematic tree is shown, representing the major topological features of the SARS-CoV-2 phylogeny. The tree is shaded to correspond to 
the major lineages and all Nextstrain and GISAID clades. Between Nextstrain clades 20A and 20C and GISAID clades G and GH, there are 
differences in the position where clades are divided (shown as grey in the main tree and lineage columns, and grey stripes in the Nextstrain 
and GISAID column). Here, the grey is shown as stripes in the Nextstrain and GISAID clade columns to reflect how they are categorised by 
each methodology. Association between the lineages and clades is approximate. The sequence data available from GISAID were curated using 
the Pangolin data preparation pipeline [8]. In brief, we masked out singleton substitutions identified in the pipeline and selected a set of 
representatives per lineage or clade. We aligned the sequences using MAFFT v7.470 [14] and estimated a maximum likelihood phylogeny using 
IQ-Tree v1.6.12 with 10,000 ultrafast bootstraps [15,16]. Sequence EPI_ISL_406801 (Wuhan/WH04/2020), a basal A lineage sequence, was 
used as an outgroup for the tree. We visualised the tree using baltic with custom python scripts and manual edits [17].
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Clade nomenclatures for SARS-CoV-2
One major component of sequence-based surveil-
lance of any pathogen is applying meaningful nomen-
clatures to the sequence data, based on the genetic 
relatedness of the sequences. This streamlines com-
munication between different actors in the molecular 
epidemiology field and enables simplified tabulation 
of the genomic data for integration with classical epi-
demiological analysis.
Several nomenclatures have been introduced for SARS-
CoV-2 (strains in GISAID use the name hCoV-19), includ-
ing by Nextstrain [6], GISAID [7] and Rambaut et al. 
(cov-lineages.org) [8-10]. While Nextstrain and GISAID 
clade nomenclatures aim at providing a broad-brush 
categorisation of globally circulating diversity, the lin-
eages (cov-lineages.org) are meant to correspond to 
outbreaks. The relation between the three nomencla-
tures is illustrated in Figure 1.
Agreement on a single nomenclature is a major global 
undertaking that cannot be decided at the national or 
European level. Major success factors of nomencla-
ture systems include adoption of the nomenclature by 
major actors in the field, fitness for purpose to the sur-
veillance objectives, compliance with the General Data 
Protection Regulation (GDPR), and availability on soft-
ware platforms. Currently, the available SARS-CoV-2 
nomenclatures do not attempt to reflect any antigenic 
or other phenotypic properties of the virus.
Distribution of clades over time
Sequence data were downloaded from GISAID on 10 
July 2020.
The subsampled distribution of clades and lineages 
over time in the WHO European Region is shown 
in Figure 2. There was an initial period in January 2020 
when the 19A/L/V/O clades (Nextstrain/GISAID nomen-
clatures) were more prevalent in total than the 20A/G 
clades, However, this could partially be an effect of 
small numbers of sequenced viral genomes in Europe 
early in the pandemic as well as the widespread sam-
pling strategy focusing on cases with travel history to 
East Asia. The 20A/G clades are characterised by the 
spike protein D614G mutation that has been suggested 
to increase transmissibility but not pathogenicity [11]. 
After this initial stage, the 20B/GR clade increased rap-
idly, stabilised around 30% between March and May 
2020 and increased further to become the most fre-
quent clade in June 2020. The trajectory for the 20C/GH 
clades differs slightly depending on the nomenclature 
applied. The Nextstrain 20C clade peaked at ca 20% of 
the sequences in early April 2020 and has since then 
slowly declined and almost disappeared, while the 
GISAID GH clade peaked at ca 30% in May 2020 and 
has rapidly declined since then. The changing trends at 
the end of the data series could partially be explained 
by different delays from sampling to publication for dif-
ferent countries with different clade distributions.
When applying the cov-lineages.org nomenclature, the 
main A and B lineages were prevalent in January and 
then diversified rapidly into sublineages which had 
stable frequencies from late February 2020 to end of 
April 2020; thereafter, an increase in the frequency of 
B.1.1 (corresponds to clade 20B/GR) and B.1.5 (part of 
clade 20A/G) lineages can be observed.
Clade distribution in the WHO European 
Region countries
The geographical distribution of Nextstrain and GISAID 
clades shows that in general, clade 19B/S has been very 
rare, except in Spain and Kazakhstan, and frequencies 
of the other clades were varied for most countries in 
the WHO European Region (Figure 3). For countries with 
few sequences, the clade distribution may be unreli-
able, and there may be a bias towards the clades that 
dominated at different stages of the pandemic depend-
ing on varying sampling strategies over time and the 
timeliness of the submission of sequences.
Among the countries with more than 100 sequences 
available, Spain stands out with a high proportion of 
clades 19B/S and 20A/G and very little of the other 
clades, Denmark, Finland and Israel with a high pro-
portion of 20C/GH, Greece, Italy, Portugal and the 
United Kingdom with no or very little 20C/GH and the 
Russian Federation and Switzerland with very little 
19A/L/V/O. The distribution may depend on founder 
effects and sampling bias, but also on when and for 
how long travel restrictions and national response 
measures were implemented. Early travel restrictions 
would probably have reduced the early incidence and 
therefore the 19A/L/V/O clades that were most preva-
lent before the 20A/G-clades became dominant, while 
travel restrictions and lockdowns implemented later 
could have preserved the clade distribution as it was 
at the time of the implementation.
Discussion about SARS-CoV-2 genomic 
surveillance in the WHO European Region
Through discussions in a call open to all laboratories 
in the WHO European region submitting SARS-CoV-2 
sequences to GISAID, we identified the following key 
surveillance objectives for the use of SARS-CoV-2 
sequence data at the European level.
Current (January 2020 and onward):
• Investigating transmission dynamics and introduc-
tions of novel genetic variants;
• Investigating the relationship between clades/line-
ages and epidemiological data such as transmissi-
bility and disease severity or risk groups to guide 
public health action;
• Understanding the impact of response measures on 
the virus population;
• Assessing the impact of mutations on the perfor-
mance of molecular diagnostic methods;
• Assessing the impact of mutations on the perfor-
mance of serological methods.
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Figure 2
Frequency trajectories of SARS-CoV-2 clades and lineages by collection date, WHO European Region, February–July 2020 
(n = 37,187, subsampled to 3,324)
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From top to bottom: Nextstrain, GISAID and cov-lineages.org. Shaded areas: interquartile ranges obtained by bootstrap resampling the dataset by 
country. Fewer sequences from fewer countries are available in recent weeks, resulting in widening confidence intervals. Frequency trajectories 
were generated from a sample representative across sampling time and space using the augur filter routine and selecting 15 random sequences 
for each month and administrative division [18]. When fewer than 15 sequences were available, all data were included. Frequencies were calcu-
lated using Gaussian smoothing with a standard deviation of 10 days. Script is available from https://github.com/neherlab/ncov-ecdc/.
5www.eurosurveillance.org
Future (when antiviral drugs and vaccines become 
available):
• Assessing the impact of mutations on the perfor-
mance of antiviral drugs;
• Assessing the impact of mutations and modelling 
the antigenic properties of the virus to assess the 
risk of vaccine escape.
All of these objectives benefit from a representative 
sample of the virus population. The first three also 
depend to a large degree on data completeness, which 
is a limitation in the currently available dataset where 
the number of sequences per country ranges from four 
to 28,000. Rapid sequencing is crucial for real-time 
outbreak analysis, for instance to show that the flare-
up in June 2020 in Beijing [12] was caused by virus 
variants similar to those circulating in Europe or to 
demonstrate separate introductions to mink farms in 
the Netherlands [13].
The experience of sequencing SARS-CoV-2 in Europe 
to date demonstrates the potential for rapidly shar-
ing genomic data to support national and international 
public health response. A genomic surveillance guid-
ance that takes the variable resources in the region 
into account is necessary to fully realise this poten-
tial. GISAID made a global, curated sharing system for 
SARS-CoV-2 sequences available early in the pandemic, 
and the benefits of available tools for early sharing of 
sequences have been demonstrated during this pan-
demic through rapid implementation of diagnostic 
tests and monitoring of the viral characteristics over 
time. Implementing real-time genomic surveillance at 
the European level could further elucidate differences 
in circulating strains between countries and enhance 
the understanding of how response measures, and 
Figure 3
Distribution of GISAID and Nextstrain clades of SARS-CoV-2 across countries in the WHO European Region, based on all 
high-quality genomes in GISAID, February– July 2020 (n = 37,187)
The numbers at the top of each bar indicate the number of available genomes. The grey areas represent sequences called differently by the 
GISAID and Nextstrain methodologies, and correspond to the grey-shaded partition of the tree in Figure 1. Supplementary Figure S3 shows 
the same data using the cov.lineages.org nomenclature. The proportion of clades found in each country was calculated using all available 
full-length, high-quality (> 27,000 bases, < 3,000 undetermined bases) sequences available on GISAID. Clade membership for each sequence 
was determined by given GISAID annotation or via the Nextstrain clades script, and proportions were calculated for all sequences from a given 
country. Script is available from https://github.com/neherlab/ncov-ecdc/
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later vaccines and antiviral drugs, affect the proportion 
of genetic variants.
Conclusions
Overall, the GISAID and Nextstrain nomenclatures pro-
vide similar pictures of the situation and may provide 
useful systems for genomic situation reporting glob-
ally. The cov-lineages.org nomenclature provides infor-
mation at a finer scale and has the potential to provide 
early warning of expanding lineages that may represent 
regional outbreaks or later become dominant because 
of some selective advantage such as vaccine escape or 
increased transmissibility.
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